Journal Home
Search for

Volume 29, Issue 8, Pages 967-969 (August 2005)


View previous. 15 of 18 View next.

Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide

C. StruppCorresponding Author Informationemail address, R. Fenk, A. Kündgen, N. Gattermann, R. Haas, U. Germing

Received 13 December 2004

Abstract 

We present a 75-year-old man who was admitted to our hospital because of splenomegaly, transfusion-dependent anemia and thrombocytopenia. The diagnosis of idiopathic myelofibrosis was suggested by the bone marrow trephine biopsy, which was hypocellular with myelofibrosis. Thalidomide was started at a daily dose of 100mg/d and increased to 400mg/d. Within 12 weeks, thrombocytes increased to 100.000/μl, hemoglobin normalized, lasting for about 11 months. Then, thalidomide had to be discontinued because of mild polyneuropathy. A second bone marrow biopsy showed fibrosis as well as a diffuse infiltration of the bone marrow (80%) by lymphocytes with expression of CD11c, CD19, CD20, CD103. Tartrate resistant acid phosphatase test (TRAP) was also positive. Hairy cell leukemia was diagnosed and he was administered 2-chlorodeoxyadenosine (2-CDA) achieving a complete remission.

Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Moorenstr. 5, 40225 Düsseldorf, Germany

Corresponding Author InformationCorresponding author. Tel.: +49 211 8117720; fax: +49 211 8118853.

PII: S0145-2126(05)00051-2

doi:10.1016/j.leukres.2005.01.007


View previous. 15 of 18 View next.